CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: April 1, 2015
Result type: Reports
Project Number: SR0428-000
Product Line: Reimbursement Review

Generic Name: Dapagliflozin

Brand Name: Forxiga

Manufacturer: AstraZeneca Canada Inc.

Therapeutic Area: Diabetes mellitus, type 2

Indications: Diabetes mellitus (Type 2)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: November 20, 2015

Recommendation Type: List with clinical criteria and/or conditions